Clinical Trials Directory

Trials / Completed

CompletedNCT07292363

Inflammation-Related Endothelial Barrier Dysfunction in Patients With Apical Periodontitis

Evaluation of Inflammation-Related Endothelial Barrier Dysfunction in Patients With Chronic Apical Periodontitis Before and After Endodontic Treatment

Status
Completed
Phase
Study type
Observational
Enrollment
45 (actual)
Sponsor
University of Turin, Italy · Academic / Other
Sex
All
Age
25 Years – 55 Years
Healthy volunteers
Accepted

Summary

Inflammation is a common factor in chronic periodontitis and systemic diseases. However, to date, there is no scientific evidence supporting a causal effect of inflammation caused by apical periodontitis on endothelial barrier dysfunction. A case-control study was designed to evaluate serum levels of endothelial barrier dysfunction factors in a sample of healthy patients aged 25 to 55, with or without apical periodontitis, before endodontic treatment and 6 and 12 months after treatment. The aim of this study is to investigate the potential relationship between the presence of chronic endodontic lesions and inflammation-related alterations of the endothelial barrier that may compromise its integrity, as well as to determine whether endodontic treatment can reduce these factors, thereby preventing changes in endothelial permeability.

Detailed description

Systemically healthy, informed, and consenting patients of both sexes under 55 years of age with a diagnosis of apical periodontitis who undergo endodontic treatment will be enrolled as cases and monitored at 6 and 12 months after treatment. Systemically healthy, informed, and consenting patients of both sexes under 55 years of age without apical periodontitis will be enrolled as control subjects. The study has been designed to assess serum levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-8 (IL-8), as well as the endothelial junctional proteins zonula occludens-1 (ZO-1), claudin-5, and vascular endothelial cadherin (VE-cadherin), using enzyme-linked immunosorbent assay (ELISA).

Conditions

Interventions

TypeNameDescription
OTHERApical lesions cureTreatment of apical lesions

Timeline

Start date
2021-02-09
Primary completion
2022-04-30
Completion
2025-10-16
First posted
2025-12-18
Last updated
2025-12-31

Locations

2 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT07292363. Inclusion in this directory is not an endorsement.